• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?

作者信息

Puxeddu Efisio, Filetti Sebastiano

机构信息

Department of Medicine, University of Perugia, Via Gambuli, 1, 06132, Perugia, Italy.

出版信息

Endocrine. 2014 Apr;45(3):341-3. doi: 10.1007/s12020-013-0139-0. Epub 2013 Dec 24.

DOI:10.1007/s12020-013-0139-0
PMID:24366644
Abstract
摘要

相似文献

1
BRAF mutation assessment in papillary thyroid cancer: are we ready to use it in clinical practice?甲状腺乳头状癌中的BRAF突变评估：我们准备好将其应用于临床实践了吗？
Endocrine. 2014 Apr;45(3):341-3. doi: 10.1007/s12020-013-0139-0. Epub 2013 Dec 24.
2
Detection of BRAF c.1799T > A (p.V600E) mutation using residual routine fine-needle aspiration specimens of papillary thyroid carcinoma.利用甲状腺乳头状癌残留的常规细针穿刺标本检测BRAF基因c.1799T > A（p.V600E）突变
Diagn Cytopathol. 2015 Oct;43(10):786-90. doi: 10.1002/dc.23302. Epub 2015 Jul 7.
3
[Studies on the BRAF T1799A gene mutation in papillary thyroid cancer: an example of translational medicine].甲状腺乳头状癌中BRAF T1799A基因突变的研究：转化医学实例
Zhonghua Nei Ke Za Zhi. 2013 Jan;52(1):5-7.
4
BRAF Testing in Multifocal Papillary Thyroid Carcinoma.多灶性乳头状甲状腺癌中的BRAF检测
Biomed Res Int. 2015;2015:486391. doi: 10.1155/2015/486391. Epub 2015 Sep 13.
5
Mutant-specific BRAF and CD117 immunocytochemistry potentially facilitate risk stratification for papillary thyroid carcinoma in fine-needle aspiration biopsy specimens.突变特异性BRAF和CD117免疫细胞化学可能有助于在细针穿刺活检标本中对甲状腺乳头状癌进行风险分层。
Tumour Biol. 2016 Jan;37(1):611-8. doi: 10.1007/s13277-015-3837-9. Epub 2015 Aug 4.
6
[BRAF-STATUS OF PAPILLARY THYROID CARCINOMAS AND STRATEGY OF SURGICAL TREATMENT].[甲状腺乳头状癌的BRAF状态与外科治疗策略]
Klin Khir. 2015 Jun(6):49-54.
7
Diagnostic value of fine needle aspiration BRAF(V600E) mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis.细针穿刺BRAF（V600E）突变分析在甲状腺乳头状癌中的诊断价值：一项系统评价和荟萃分析
Hum Pathol. 2015 Oct;46(10):1443-54. doi: 10.1016/j.humpath.2015.06.001. Epub 2015 Jun 16.
8
The correlation of sodium iodide symporter and BRAF(V600E) mutation in classical variant papillary thyroid carcinoma.经典型乳头状甲状腺癌中碘化钠转运体与BRAF（V600E）突变的相关性
Ann Diagn Pathol. 2016 Jun;22:58-62. doi: 10.1016/j.anndiagpath.2016.04.002. Epub 2016 Apr 9.
9
[BRAF gene mutation in the natural history of papillary thyroid carcinoma: diagnostic and prognostic implications].[BRAF基因变异在甲状腺乳头状癌自然病程中的诊断及预后意义]
Acta Med Port. 2011 Dec;24 Suppl 4:855-68. Epub 2011 Dec 31.
10
Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.原发性和转移性乳头状甲状腺癌中BRAF V600E突变的特异性免疫组化检测
Exp Mol Pathol. 2016 Feb;100(1):236-41. doi: 10.1016/j.yexmp.2016.01.004. Epub 2016 Jan 13.

引用本文的文献

1
New biomarkers: prospect for diagnosis and monitoring of thyroid disease.新生物标志物：甲状腺疾病的诊断和监测前景。
Front Endocrinol (Lausanne). 2023 Jul 21;14:1218320. doi: 10.3389/fendo.2023.1218320. eCollection 2023.
2
Regulation of MEK inhibitor selumetinib sensitivity by AKT phosphorylation in the novel BRAF L525R mutant.新型 BRAF L525R 突变体中 AKT 磷酸化对 MEK 抑制剂 selumetinib 敏感性的调节。
Int J Clin Oncol. 2023 May;28(5):654-663. doi: 10.1007/s10147-023-02318-w. Epub 2023 Mar 1.
3
Comparison of diagnostic methods for the detection of a BRAF mutation in papillary thyroid cancer.

本文引用的文献

1
Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers.BRAF V600E 突变是否预示甲状腺乳头癌的侵袭性特征？来自四个内分泌外科中心的研究结果。
J Clin Endocrinol Metab. 2013 Sep;98(9):3702-12. doi: 10.1210/jc.2013-1584. Epub 2013 Aug 22.
2
The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis.甲状腺癌伴术前细胞学阳性或可疑发现的 BRAF V600E 突变与晚期或预后不良无关。
Endocrine. 2014 Apr;45(3):462-8. doi: 10.1007/s12020-013-0029-5. Epub 2013 Aug 8.
3
甲状腺乳头状癌中BRAF突变检测诊断方法的比较
Oncol Lett. 2019 May;17(5):4661-4666. doi: 10.3892/ol.2019.10131. Epub 2019 Mar 8.
4
BRAF-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response.SWIM 分析揭示 BRAF 突变型癌症的多种网络：预测威罗菲尼的临床反应。
Endocrine. 2019 May;64(2):406-413. doi: 10.1007/s12020-019-01890-4. Epub 2019 Mar 8.
5
Utility of including BRAF mutation analysis with ultrasonographic and cytological diagnoses in ultrasonography-guided fine-needle aspiration of thyroid nodules.在超声引导下甲状腺结节细针抽吸中，将 BRAF 基因突变分析与超声和细胞学诊断相结合的效用。
PLoS One. 2018 Aug 17;13(8):e0202687. doi: 10.1371/journal.pone.0202687. eCollection 2018.
6
PDE5 Overexpression in Well-Differentiated Thyroid Carcinomas Is Associated with Lymph Node Metastasis.磷酸二酯酶5在高分化甲状腺癌中的过表达与淋巴结转移相关。
Int J Endocrinol. 2017;2017:6243932. doi: 10.1155/2017/6243932. Epub 2017 Oct 1.
7
mutation in prognostication of papillary thyroid cancer (PTC) recurrence.甲状腺乳头状癌（PTC）复发预后中的突变
Gland Surg. 2016 Oct;5(5):495-505. doi: 10.21037/gs.2016.09.09.
8
Diagnostic value of BRAF (V600E)-mutation analysis in fine-needle aspiration of thyroid nodules: a meta-analysis.BRAF（V600E）突变分析在甲状腺结节细针穿刺中的诊断价值：一项荟萃分析。
Onco Targets Ther. 2016 Apr 27;9:2495-509. doi: 10.2147/OTT.S101800. eCollection 2016.
9
A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.免疫组织化学和分子方法相结合可提高甲状腺乳头状癌中BRAF突变的高灵敏度检测。
Endocrine. 2016 Sep;53(3):672-80. doi: 10.1007/s12020-015-0720-9. Epub 2015 Aug 22.
10
BRAF V600E and risk stratification of thyroid microcarcinoma: a multicenter pathological and clinical study.BRAF V600E与甲状腺微小癌的风险分层：一项多中心病理与临床研究
Mod Pathol. 2015 Oct;28(10):1343-59. doi: 10.1038/modpathol.2015.92. Epub 2015 Aug 14.
Immunohistochemical detection of mutated BRAF V600E supports the clonal origin of BRAF-induced thyroid cancers along the spectrum of disease progression.
免疫组化检测 BRAF V600E 突变支持 BRAF 诱导的甲状腺癌在疾病进展过程中沿谱系起源于克隆。
J Clin Endocrinol Metab. 2013 Aug;98(8):E1414-21. doi: 10.1210/jc.2013-1408. Epub 2013 Jun 17.
4
Progress in molecular-based management of differentiated thyroid cancer.分化型甲状腺癌的分子靶向治疗进展。
Lancet. 2013 Mar 23;381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9. Epub 2013 Mar 22.
5
Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.BRAF V600E 突变与甲状腺乳头状癌患者死亡率的关系。
JAMA. 2013 Apr 10;309(14):1493-501. doi: 10.1001/jama.2013.3190.
6
Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.伴有 BRAF(V600E) 突变的转移性甲状腺乳头状癌患者对 vemurafenib 的临床反应。
Thyroid. 2013 Oct;23(10):1277-83. doi: 10.1089/thy.2013.0057. Epub 2013 Jul 17.
7
Thin core biopsy should help to discriminate thyroid nodules cytologically classified as indeterminate. A new sampling technique.细针穿刺活检有助于鉴别细胞学分类为不确定的甲状腺结节。一种新的取样技术。
Endocrine. 2013 Jun;43(3):659-65. doi: 10.1007/s12020-012-9811-z. Epub 2012 Oct 16.
8
Ultrasound sensitivity for thyroid malignancy is increased by real-time elastography: a prospective multicenter study.实时超声弹性成像技术提高甲状腺恶性肿瘤的超声诊断敏感度：一项前瞻性多中心研究。
J Clin Endocrinol Metab. 2012 Dec;97(12):4524-30. doi: 10.1210/jc.2012-2951. Epub 2012 Oct 12.
9
Preoperative diagnosis of benign thyroid nodules with indeterminate cytology.术前诊断不确定细胞学的良性甲状腺结节。
N Engl J Med. 2012 Aug 23;367(8):705-15. doi: 10.1056/NEJMoa1203208. Epub 2012 Jun 25.
10
The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma.BRAF(V600E) 的原发性发生是甲状腺乳头状癌中罕见的克隆事件。
J Clin Endocrinol Metab. 2012 Feb;97(2):517-24. doi: 10.1210/jc.2011-0618. Epub 2011 Dec 14.